Compare · GLP-1 agonist
Orforglipron vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Orforglipron | VK2735 | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
Orforglipron
Orforglipron (brand name Foundayo) is a GLP-1 receptor agonist — the same drug class as semaglutide and tirzepatide — but with one defining difference: it is a small molecule, not a peptide, and it is taken as a once-daily pill rather than an injection. In April 2026 the FDA approved it for chronic…
VK2735
VK2735 is an investigational obesity drug from Viking Therapeutics. It belongs to the incretin class — the same broad family as semaglutide and tirzepatide — and has generated a lot of attention because its early human data look strong and because Viking is developing both an injectable and an oral…